chinese/抗癌药

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel microorganism isolated from Chinese elm(Ulmus sp.) and a process for preparing immunostimulating exopolysaccharides with anticancer activity by employing the microorganism, more specifically, to a novel

TECHNICAL FIELD This invention relates to a composition derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to its use for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs. More specifically, the composition of the present

FIELD OF THE INVENTION The present invention relates to a composition having an anticancer activity containing components derived from natural substances as active components and more particularly to a composition having anticancer activity containing dry products of certain plants. BACKGROUND OF

FIELD OF THE INVENTION The present invention relates to compositions for treatment of cancer and specifically, tumors. More particularly, the present invention is directed to anti-neoplastic compositions comprising a particular combination of herbs. BACKGROUND OF THE INVENTION According to the data

The present invention relates to polypeptide-containing compound(s) (hereinafter "PROTEINA"), composition(s) comprising such compound(s) along with divalent metal ions and/or a carbohydrate moiety (hereinafter "ALICIN"), their antiviral and anti-hepatoma activities, and the enhancement of activity

BACKGROUND OF THE INVENTION Auto-immune diseases affect nearly 24 million people in the United States (roughly 8% of the population) alone making it one of the most prevalent diseases. By comparison, heart disease affects 22 million and cancer 9 million. Many auto-immune diseases are correlated with

CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of U.S. patent application Ser. No. 13/758,921, filed Feb. 4, 2013, which claims the benefit of U.S. Provisional Patent Application No. 61/594,934, filed Feb. 3, 2012; and U.S. Provisional Patent Application No.

CROSS REFERENCE OF RELATED APPLICATION This is a U.S. National Stage under 35 U.S.C 371 of the International Application PCT/CN2012/000801, filed Jun. 12, 2012, which claims priority under 35 U.S.C. 119(a-d) to CN 201110371955.4, filed Nov. 22, 2011. BACKGROUND OF THE PRESENT INVENTION Field of

FIELD OF THE INVENTION The present invention relates to a medication combination, consisting of Baizhu, Danggui, Hanxincao, Huotanmucao, Ainaxiang, Shuodiao, Malan, Ludou, Canger, Daqinggen, Banbianlian, Xingren, Nuzhenzi, Qianhu, Jiatonghao, Yinchenhao, Yujin, Zhishi, Banxia, and Fuling for

BACKGROUND OF THE INVENTION Signal Transducer and Activator of Transcription (STAT) proteins have essential functions in normal cytokine signaling and are frequently constitutively activated in human tumor cells (Yu and Jove, 2004). STATs have key roles in regulating cell proliferation, survival,

DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The substance of the present invention is an antitumor-proteinaceous substance that is released into the culture supernatant by cultured cells such as mammalian cultured cells that are able to proliferate without any restriction and to